Protara Research Development vs Net Income From Continuing Ops Analysis

TARA Stock

USD 3.01 0.03 0.99%

Protara Therapeutics financial indicator trend analysis is much more than just breaking down Protara Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protara Therapeutics is a good investment. Please check the relationship between Protara Therapeutics Research Development and its Net Income From Continuing Ops accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.

Research Development vs Net Income From Continuing Ops

Research Development vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protara Therapeutics Research Development account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have pay attention.

The correlation between Protara Therapeutics' Research Development and Net Income From Continuing Ops is -0.82. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Protara Therapeutics, assuming nothing else is changed. The correlation between historical values of Protara Therapeutics' Research Development and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Protara Therapeutics are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Research Development i.e., Protara Therapeutics' Research Development and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

-0.82

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Research Development

Net Income From Continuing Ops

Most indicators from Protara Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protara Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.At present, Protara Therapeutics' Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.31, whereas Selling General Administrative is forecasted to decline to about 15.3 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	117K	248K	309K	231.7K
Interest Income	2.0M	2.2M	3.0M	3.1M

Reconciled Depreciation Interest Income

Protara Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Retained Earnings Total Equity	Common Stock Shares Outstanding	Short Term Investments	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Other Assets
Total Assets		-0.26	0.0	1.0	0.93	0.45	-0.66	0.74	0.3	0.71	0.76	0.5	0.92	-0.51	0.81	0.55	0.4	0.45	0.05	0.23	0.32	0.44	0.92	-0.16	0.39	0.89
Other Current Liab	-0.26		0.83	-0.29	-0.36	-0.14	0.26	-0.26	-0.25	-0.27	-0.16	-0.12	-0.26	0.46	-0.33	-0.14	0.04	-0.14	0.13	0.17	0.39	-0.13	-0.26	0.47	-0.13	-0.12
Total Current Liabilities	0.0	0.83		-0.06	-0.01	0.39	0.32	-0.31	0.25	-0.29	0.15	0.33	-0.1	0.02	0.14	0.37	0.44	0.36	0.57	0.5	0.82	0.4	-0.09	0.21	0.4	0.01
Total Stockholder Equity	1.0	-0.29	-0.06		0.93	0.4	-0.69	0.77	0.27	0.74	0.73	0.47	0.93	-0.49	0.79	0.5	0.35	0.41	0.0	0.18	0.26	0.39	0.94	-0.15	0.34	0.89
Net Tangible Assets	0.93	-0.36	-0.01	0.93		0.45	-0.65	0.72	0.48	0.7	0.6	0.56	0.91	-0.55	0.91	0.54	0.39	0.5	0.22	0.15	0.32	0.46	0.92	-0.15	0.43	0.8
Property Plant And Equipment Net	0.45	-0.14	0.39	0.4	0.45		0.29	-0.16	0.69	-0.2	0.74	0.7	0.17	-0.71	0.69	0.94	0.79	0.8	0.64	0.71	0.82	1.0	0.18	-0.49	0.98	0.24
Net Debt	-0.66	0.26	0.32	-0.69	-0.65	0.29		-0.79	0.01	-0.99	-0.08	-0.19	-0.86	0.07	-0.39	0.07	0.36	0.03	0.36	0.26	0.34	0.28	-0.85	-0.11	0.29	-0.6
Retained Earnings	0.74	-0.26	-0.31	0.77	0.72	-0.16	-0.79		-0.16	0.77	0.33	-0.1	0.83	-0.02	0.44	-0.12	0.06	-0.17	-0.34	-0.38	-0.19	-0.18	0.83	0.24	-0.24	0.85
Accounts Payable	0.3	-0.25	0.25	0.27	0.48	0.69	0.01	-0.16		0.08	0.2	0.82	0.28	-0.52	0.77	0.74	0.42	0.61	0.62	0.36	0.48	0.74	0.29	-0.3	0.79	0.0
Cash	0.71	-0.27	-0.29	0.74	0.7	-0.2	-0.99	0.77	0.08		0.14	0.28	0.89	-0.14	0.47	0.02	-0.31	0.04	-0.31	-0.2	-0.28	-0.18	0.89	0.07	-0.19	0.61
Non Current Assets Total	0.76	-0.16	0.15	0.73	0.6	0.74	-0.08	0.33	0.2	0.14		0.46	0.44	-0.61	0.58	0.71	0.63	0.6	0.3	0.57	0.58	0.71	0.45	-0.37	0.65	0.63
Non Currrent Assets Other	0.5	-0.12	0.33	0.47	0.56	0.7	-0.19	-0.1	0.82	0.28	0.46		0.41	-0.69	0.72	0.86	0.26	0.82	0.59	0.68	0.55	0.74	0.42	-0.48	0.79	0.13
Cash And Short Term Investments	0.92	-0.26	-0.1	0.93	0.91	0.17	-0.86	0.83	0.28	0.89	0.44	0.41		-0.34	0.76	0.32	0.16	0.25	-0.12	-0.03	0.08	0.18	1.0	0.0	0.14	0.84
Common Stock Total Equity	-0.51	0.46	0.02	-0.49	-0.55	-0.71	0.07	-0.02	-0.52	-0.14	-0.61	-0.69	-0.34		-0.6	-0.74	-0.41	-0.82	-0.34	-0.62	-0.43	-0.7	-0.34	0.88	-0.7	-0.23
Retained Earnings Total Equity	0.81	-0.33	0.14	0.79	0.91	0.69	-0.39	0.44	0.77	0.47	0.58	0.72	0.76	-0.6		0.74	0.57	0.59	0.39	0.26	0.5	0.71	0.77	-0.22	0.69	0.61
Common Stock Shares Outstanding	0.55	-0.14	0.37	0.5	0.54	0.94	0.07	-0.12	0.74	0.02	0.71	0.86	0.32	-0.74	0.74		0.62	0.89	0.62	0.78	0.76	0.95	0.33	-0.48	0.95	0.28
Short Term Investments	0.4	0.04	0.44	0.35	0.39	0.79	0.36	0.06	0.42	-0.31	0.63	0.26	0.16	-0.41	0.57	0.62		0.43	0.43	0.38	0.78	0.77	0.17	-0.15	0.71	0.43
Capital Surpluse	0.45	-0.14	0.36	0.41	0.5	0.8	0.03	-0.17	0.61	0.04	0.6	0.82	0.25	-0.82	0.59	0.89	0.43		0.69	0.83	0.72	0.8	0.26	-0.59	0.82	0.18
Other Current Assets	0.05	0.13	0.57	0.0	0.22	0.64	0.36	-0.34	0.62	-0.31	0.3	0.59	-0.12	-0.34	0.39	0.62	0.43	0.69		0.56	0.73	0.67	-0.1	-0.11	0.7	-0.15
Other Stockholder Equity	0.23	0.17	0.5	0.18	0.15	0.71	0.26	-0.38	0.36	-0.2	0.57	0.68	-0.03	-0.62	0.26	0.78	0.38	0.83	0.56		0.72	0.7	-0.02	-0.53	0.7	0.06
Total Liab	0.32	0.39	0.82	0.26	0.32	0.82	0.34	-0.19	0.48	-0.28	0.58	0.55	0.08	-0.43	0.5	0.76	0.78	0.72	0.73	0.72		0.82	0.1	-0.15	0.79	0.24
Property Plant And Equipment Gross	0.44	-0.13	0.4	0.39	0.46	1.0	0.28	-0.18	0.74	-0.18	0.71	0.74	0.18	-0.7	0.71	0.95	0.77	0.8	0.67	0.7	0.82		0.19	-0.46	0.99	0.21
Total Current Assets	0.92	-0.26	-0.09	0.94	0.92	0.18	-0.85	0.83	0.29	0.89	0.45	0.42	1.0	-0.34	0.77	0.33	0.17	0.26	-0.1	-0.02	0.1	0.19		0.0	0.16	0.84
Common Stock	-0.16	0.47	0.21	-0.15	-0.15	-0.49	-0.11	0.24	-0.3	0.07	-0.37	-0.48	0.0	0.88	-0.22	-0.48	-0.15	-0.59	-0.11	-0.53	-0.15	-0.46	0.0		-0.49	0.12
Property Plant Equipment	0.39	-0.13	0.4	0.34	0.43	0.98	0.29	-0.24	0.79	-0.19	0.65	0.79	0.14	-0.7	0.69	0.95	0.71	0.82	0.7	0.7	0.79	0.99	0.16	-0.49		0.12
Other Assets	0.89	-0.12	0.01	0.89	0.8	0.24	-0.6	0.85	0.0	0.61	0.63	0.13	0.84	-0.23	0.61	0.28	0.43	0.18	-0.15	0.06	0.24	0.21	0.84	0.12	0.12

Click cells to compare fundamentals

Protara Therapeutics Account Relationship Matchups

Protara Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.0M	203.2M	172.6M	113.3M	79.0M	92.2M
Other Current Liab	320K	1.7M	1.6M	2.3M	1.7M	2.3M
Total Current Liabilities	583K	2.9M	4.3M	5.7M	6.1M	4.8M
Total Stockholder Equity	6.4M	199.2M	161.9M	102.1M	68.3M	85.5M
Net Tangible Assets	(12.1M)	169.7M	132.4M	102.1M	117.4M	71.9M
Property Plant And Equipment Net	459K	1.2M	8.9M	7.9M	6.6M	6.9M
Net Debt	(6.2M)	(167.5M)	(28.5M)	(17.7M)	(34.1M)	(35.8M)
Retained Earnings	(225.5M)	(46.8M)	(94.0M)	(160.0M)	(200.4M)	(210.4M)
Accounts Payable	263K	914K	954K	1.6M	2.4M	2.6M
Cash	6.2M	168.6M	35.7M	24.1M	39.6M	50.6M
Non Current Assets Total	581K	33.7M	79.5M	27.1M	10.2M	16.9M
Non Currrent Assets Other	122K	3.0M	1.6M	1.4M	3.7M	3.9M
Cash And Short Term Investments	6.2M	168.6M	91.2M	84.4M	65.6M	73.7M
Retained Earnings Total Equity	(189.7M)	(210.5M)	(225.5M)	(46.8M)	(42.1M)	(44.2M)
Common Stock Shares Outstanding	64.4K	7.2M	11.2M	11.3M	11.3M	11.9M
Liabilities And Stockholders Equity	7.0M	203.2M	172.6M	113.3M	79.0M	92.2M
Capital Surpluse	203.0M	209.4M	213.4M	246.0M	282.9M	228.9M
Other Current Assets	744K	837K	1.9M	1.3M	2.9M	1.6M
Other Stockholder Equity	213.4M	246.0M	256.1M	262.7M	268.7M	237.6M
Total Liab	583K	3.9M	10.7M	11.2M	10.6M	6.7M
Property Plant And Equipment Gross	0.0	1.2M	8.9M	7.9M	7.4M	7.8M
Total Current Assets	7.0M	169.4M	93.1M	86.1M	68.7M	75.4M
Accumulated Other Comprehensive Income	3K	0.0	(211K)	(688K)	(31K)	(32.6K)
Common Stock	18K	19K	3K	11K	9.9K	10.6K
Property Plant Equipment	459K	1.2M	8.9M	7.9M	9.0M	9.5M
Other Assets	(581K)	1.9M	1.6M	1.4M	1.0	0.95
Non Current Liabilities Total	263K	999K	6.4M	5.5M	4.5M	3.2M
Net Invested Capital	(12.1M)	199.2M	161.9M	102.1M	68.3M	95.0M
Net Working Capital	6.4M	166.5M	88.8M	80.4M	62.6M	77.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:

How To Invest In Protara

Details

Is Protara Stock a good investment?

Details

What is Protara Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.64)

Return On Assets

(0.28)

Return On Equity

(0.46)

The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protara Research Development vs Net Income From Continuing Ops Analysis

Research Development vs Net Income From Continuing Ops

Research Development vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Research Development

Net Income From Continuing Ops

Protara Therapeutics fundamental ratios Correlations

Protara Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protara Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant Equipment	+ 0.99	Property Plant And Equipment Gross
Property Plant Equipment	+ 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.95	Common Stock Shares Outstanding

Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.86	Net Debt
Total Current Assets	- 0.85	Net Debt
Capital Surpluse	- 0.82	Common Stock Total Equity
Retained Earnings	- 0.79	Net Debt
Common Stock Shares Outstanding	- 0.74	Common Stock Total Equity